Neurology Central

Galanin identified as new therapeutic target for the treatment of depression

A research group from the University of Málaga (Spain) have determined that a fragment of the neuropeptide galanin promotes anhedonia. The results of their paper, published in the Journal of Psychopharmacology, suggest that the galanin fragment could be a therapeutic target for the treatment of depression.

The group have been analyzing the role of galanin in neuropsychiatric diseases since 2007 and have now demonstrated that the N-terminal (1-15) fragment of the protein plays a role in the brain’s reward system.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.